Citations

Clear

415 citation(s) found for "Snyder, EM".

Optimizing Assessment of Contraction Reserve in Ineffective Esophageal Motility: A Study of Upright Multiple Rapid Swallows
Li, Tian , Codipilly, Don C. , Snyder, Diana L. , Pang, Maoyin , Koop, Andree , Snyder, Diana, Ravi, Karthik

Mayo Clinic

Journal of Neurogastroenterology and Motility | January 9, 2025 | Volume: 31 | Issue: 1 | Pages: 38-44

10.5056/jnm24097 | PMID 39779202 Get It

The POINTER Imaging baseline cohort: Associations between multimodal neuroimaging biomarkers, cardiovascular health, and cognition
Harrison, Theresa M. , Ward, Tyler J. , Taggett, Jacinda , Maillard, Pauline , Jung, Youngkyoo , Lovato, Laura, Jagust, William J., Harvey, Danielle , Masdeu, Joseph C. , Oh, Hwamee , Aggarwal, Neelum T. , Cleveland, Maryjo, Whitmer, Rachel A. , Farias, Sarah Tomaszewski , Salloway, Stephen , Pavlik, Valory , Yu, Melissa , Snyder, Heather M. , Carrillo, María C. , Baker, Laura D. , DeCarli, Charles , Landau, Susan, Group, for the U.S. POINTER Study, DeCarli, Charles , Harvey, Danielle J , Maillard, Pauline , Harrison, Theresa M , Lockhart, Samuel N. , Koeppe, Robert A. , Masdeu, Joseph C , Gitelman, Darren R. , Espeland, Mark Andrew , Tangney, Christy , Vemuri, Prashanthi , Group, for the U.S. POINTER Study

Mayo Clinic

Alzheimer's & Dementia | December 6, 2024 | Volume: 21 | Issue: 1 | Pages: No page available

10.1002/alz.14399 | PMID 39641363 Get It

Abstract INTRODUCTION The U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER) is evaluating lifestyle interventions in older adults at risk for cognitive decline and dementia. Here we characterize the baseline data set of the POINTER Imaging ancillary study. METHODS Participants underwent health and cognitive assessments and neuroimaging with multimodal positron emission tomography (PET) (beta‐amyloid [Aβ] and tau) and magnetic resonance imaging (MRI). Framingham risk score (FRS) was used to quantify cardiovascular disease (CVD) risk. RESULTS A total of 1052 participants (31% from underrepresented ethnoracial groups) were enrolled. Compared to Aβ−, Aβ+ (29%) participants were older, had higher apolipoprotein E ( APOE ) ε4 carriage rate and white matter hyperintensity volume, and greater temporal tau. FRS was related to MRI measures, but not AD biomarkers. FRS and tau had independent effects on cognition. DISCUSSION In this heterogenous, at‐risk cohort, CVD risk was related to more abnormal brain structure and poorer cognition, representing a putative non‐AD (Alzheimer's disease) pathway to brain injury and cognitive decline. Highlights The U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER) cohort is enriched for cardiovascular disease (CVD) and poor lifestyle POINTER Imaging collected multimodal neuroimaging data in this unique, at‐risk cohort Amyloid burden was related to age, apolipoprotein E ( APOE ) ε4 carriage, and measures of disease progression Associations between amyloid and tau, and tau and cognition, were relatively weak CVD risk and tau pathology were independently related to memory
Transfusion Efficacy and Safety of Amustaline/Glutathione Pathogen-Reduced Red Blood Cells: Results of a Randomized, Controlled Phase III Trial
Snyder, Edward L. , Sekela, Michael , Toyoda, Yoshiya , Alsammak, Mohamed , Sodha, Neel R. , Beaver, Thomas M., Pelletier, J. Peter R. , Gorham, James D. , McNeil, John S. , Pearl, Ronald G. , Nuttall, Gregory A. , Reece, T. Brett , Davenport, Robertson D., Benharash, Peyman , Lopez‐Plaza, Ileana, Sadler, Patrick, Reik, Rita A., Mufti, Nina, Varrone, Jeanne, Benjamin, Richard J , Welsby, Ian J , Beaver, Thomas M. , Sniecinski, Roman M , Sarode, Ravi , Kaplan, Alesia , Ipe, Tina S. , Gammon, Richard R. , Corash, Laurence M , Liu, Kathy

Mayo Clinic

Blood | December 5, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 5592-5592

10.1182/blood-2024-202164 Get It

Introduction: Red blood cell (RBC) transfusion is a lifesaving intervention with a low but persistent risk of transfusion-transmitted infection. Amustaline/glutathione RBC pathogen-reduction (PR) technology is designed to proactively inactivate a broad spectrum of viruses, bacteria, protozoa and leukocytes by chemically crosslinking nucleic acids and preventing replication and transcription. The Red Cell Pathogen Inactivation (ReCePI) trial was a Phase III, double-blinded, randomized non-inferiority study comparing PR and conventional RBCs for the support of acute anemia. Methods/Study Design: Complex cardiac or thoracic-aorta surgery patients received conventional (Control) or PR RBCs (Test) during and for 7 days after surgery. The protocol was conducted with ethics committee approval at all participating centers and written informed consent from all participants. Hemoglobin levels, blood utilization and serum creatinine were assessed as indicators of efficacy and oxygenation of tissues (Karkouti et al. Br J Anaesth. 2012; 109 Suppl 1: i29-i38). The primary endpoint was the incidence of acute kidney injury (AKI) measured as change in serum creatinine from baseline within 48 hours of surgery, a predictor of adverse postoperative outcomes including mortality by Day 30 post-surgery (Lassnig et al. Am Soc Nephrol 2004; 1597-1605). Secondary endpoints included AKI occurring up to 7 days post-surgery (KDIGO Clinical Practice Guideline for AKI, Kidney Inter, Suppl. 2012;2:1-138); death or the need for renal replacement therapy by 30 days post-surgery; PR RBC-specific antibodies; and death by day 75 post-surgery. With >292 subjects enrolled, the study had 80% power to demonstrate non-inferiority, assuming an AKI incidence of 30% with conventional RBCs and a non-inferiority margin of half the conventional RBC rate. Under these circumstances, an absolute treatment increase of 5% in the AKI rate in the PR RBC arm would fail the non-inferiority test. This work was supported by a contract with the US Biomedical Advanced Research and Development Authority (HHS010020160009c) with Cerus Corporation. Results: Five-hundred and eighty-one subjects were randomized and 321 (55%) transfused in 18 US hospitals. In the modified intent-to-treat analysis subjects receiving Test and Control RBCs had similar median [IQR] total blood loss (1500 [940-2475] mL Test, 1733 [1060-2880] mL Control, p=0.310) and comparable median hemoglobin levels at baseline and immediately post-surgery (9.8 [8.9-10.9] g/dL Test, 9.6 [8.6-10.6] g/dL Control, p=0.157) and for 7 days after surgery, The PR RBC arm was transfused with fewer RBCs, measured as total RBC Hb transfused over 7-days (169.0 [102.0-240.0] g Hb PR arm, 188.0 [126.0-295.0] g Hb, conventional RBC arm, p=0.008). The incidence of AKI was 29.3% (46/157) for Test and 28.0% (45/161) for Control. The treatment difference was 0.74% (95% CI -8.9, 10.4%, non-inferiority margin 14.0%, p=0.001 for non-inferiority). Non-inferiority was also achieved by the per protocol analysis. Average mean change in serum creatinine within 48 hours of surgery was comparable (Test 0.020, Control 0.23 mg/dL, P=0.515). Adverse events, serious adverse events and deaths on study were not different. Five of 159 (3.1%) PR RBC recipients developed low titer PR RBC-specific antibodies without clinical signs of hemolysis. Flow cytometry analysis revealed persistent circulating PR RBCs with uniform antigen loss (modulation). Low level human IgG antibody binding was demonstrated in 3 of 5 subjects. Conclusions: PR RBCs showed equivalent hemoglobin support for acute bleeding patients undergoing cardiac or thoracic-aorta surgery while using less transfused total RBC Hb over 7 days. The incidence of AKI in patients transfused with PR RBCs was non-inferior to that observed with conventional RBCs, indicative of effective tissue oxygenation. Treatment-related antibodies to PR-RBC were observed only in Test subjects, the antibodies were low titer, transient, without clinical hemolysis, and persistent circulating PR RBCs were detected with modulated low level acridine antigen expression (www.clinicaltrials.gov #NCT03459287).
Single-cell multiomics reveal divergent effects of DNMT3A- and TET2- mutant clonal hematopoiesis in inflammatory response
Ismail, Wazim Mohammed , Binder, Moritz , Kim, Minsuk , Geyer, Susan M. , Mazzone, Amelia , Finke, Christy M. , Mangaonkar, Abhishek A. , Lee, Jeong‐Heon , Kim, Kwan‐Hyun , Simon, Vernadette, Rohakthar, Fariborz Rakhshan, Munankarmy, Amik , Byeon, Seul Kee , Schwager, Susan M., Harington, Jonathan J., Snyder, Melissa R. , Wieben, Eric D. , Gaspar‐Maia, Alexandre , Patnaik, Mrinal M. , Mohammed Ismail, Wazim , Fernandez, Jenna A., Binder, Moritz , Kim, Minsuk , Mazzone, Amelia , Lee, Jeong-Heon , Wang, Liguo , Kim, Kwan Hyun , Simon, Vernadette A, Rakhshan Rohakthar, Fariborz, Munankarmy, Amik , Byeon, Seul Kee , Harrington, Jonathan J. , Robertson, Keith D , Pandey, Akhilesh , Gaspar-Maia, Alexandre , Patnaik, Mrinal , Fernandez, Jenna , Lasho, Terra L. , Wang, Liguo , Robertson, Keith D. , Pandey, Akhilesh , Chia, Nicholas

Mayo Clinic

Blood Advances | December 4, 2024 | Volume: 9 | Issue: 2 | Pages: 402-416

10.1182/bloodadvances.2024014467 | PMID 39631069 Get It

Abstract DNMT3A and TET2 are epigenetic regulator genes commonly mutated in age-related clonal hematopoiesis (CH). Despite having opposed epigenetic functions, these mutations are associated with increased all-cause mortality and a low risk for progression to hematologic neoplasms. Although individual impacts on the epigenome have been described using different model systems, the phenotypic complexity in humans remains to be elucidated. Here, we make use of a natural inflammatory response occurring during coronavirus disease 2019 (COVID-19), to understand the association of these mutations with inflammatory morbidity (acute respiratory distress syndrome [ARDS]) and mortality. We demonstrate the age-independent, negative impact of DNMT3A mutant (DNMT3Amt) CH on COVID-19–related ARDS and mortality. Using single-cell proteogenomics we show that DNMT3A mutations involve myeloid and lymphoid lineage cells. Using single-cell multiomics sequencing, we identify cell-specific gene expression changes associated with DNMT3A mutations, along with significant epigenomic deregulation affecting enhancer accessibility, resulting in overexpression of interleukin-32 (IL-32), a proinflammatory cytokine that can result in inflammasome activation in monocytes and macrophages. Finally, we show with single-cell resolution that the loss of function of DNMT3A is directly associated with increased chromatin accessibility in mutant cells. Hence, we demonstrate the negative prognostic impact of DNMT3Amt CH on COVID-19–related ARDS and mortality. DNMT3Amt CH in the context of COVID-19, was associated with inflammatory transcriptional priming, resulting in overexpression of IL32. This overexpression was secondary to increased chromatic accessibility, specific to DNMT3Amt CH cells. DNMT3Amt CH can thus serve as a potential biomarker for adverse outcomes in COVID-19.
Best Practices for Delivering Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma
Cloyd, Jordan M. , Sarna, Angela, Arango, Matthew J. , Bates, Susan E. , Bloomston, Mark, Ferrone, Cristina R., Gambino, Patricia, Goenka, Ajit H. , Hall, William A. , Jayaraman, Shiva , Kambadakone, Avinash, Ko, Andrew , Kooby, David A. , Krishna, Somashekar G. , Larsson, Liliana, Massarweh, Nader N. , Mikhail, Sameh , Palta, Manisha , Petzel, Maria Q. B., Philip, P. A., Mina, Daniel Santa , Sohal, Davendra , Sundaresan, Tilak , Tsai, Susan, Vreeland, Timothy J. , Walston, Steve, Wo, Jennifer Y. , Snyder, Rebecca A. , He, Jin , Tsai, Susan , Krishna, Somashekar G , Santa Mina, Daniel , Bates, Susan E , Bhutani, Manoop S. , Chung, Vincent , Dotan, Efrat , Goodman, Karyn A. , He, Jing , Hogg, Melissa E. , Katz, Matthew H. G. , Khorana, Alok A. , Koay, Eugene J. , Lee, Richard T. , Maitra, Anirban , Muzaffar, Mahvish , O’Reilly, Eileen M. , Reyngold, Marsha , Turner, Kea L. , Washington, Mary Kay , Williams, Terence M. , Snyder, Rebecca A.

Mayo Clinic

JAMA Surgery | December 4, 2024 | Volume: 160 | Issue: 2 | Pages: 172

10.1001/jamasurg.2024.5191 | PMID 39630427 Get It

Importance Neoadjuvant therapy (NT) is an increasingly used treatment strategy for patients with localized pancreatic ductal adenocarcinoma (PDAC). Little research has been conducted on cancer care delivery during NT, and the standards for optimal delivery of NT have not been defined. Objective To develop consensus best practices for delivering NT to patients with localized PDAC. Design, Setting, and Participants This study used a modified Delphi approach consisting of 2 rounds of voting, and a series of virtual conferences (from October to December 2023) to reach expert consensus on candidate best practice statements generated from a systematic review of the literature and expert opinion. An interdisciplinary panel was formed including 47 North American experts from surgical, medical, and radiation oncology, radiology, pathology, gastroenterology, integrative oncology, anesthesia, pharmacy, nursing, cancer care delivery research, and nutrition as well as patient and caregiver stakeholders. Main Outcome and Measures Statements that reached 75% agreement or greater were included in final consensus statements. Results Of the 47 participating panel members, 27 (57.64%) were male, and the mean (SD) age was 47.6 (8.2) years. Physicians reported completing training a mean (SD) 14.6 (8.6) years prior and seeing a mean (SD) 110.6 (38.4) patients with PDAC annually; 35 (77.7%) were in academic practice. Final consensus was reached on 82 best practices for delivering NT. Of these, 38 statements focused on pre-NT practices, including diagnosis and staging (n = 15), evaluation and optimization (n = 20), and decision-making (n = 3); 29 statements defined best practices during NT, including initiation (n = 3), delivery of therapy (n = 8), restaging practices (n = 12), and management of complications during NT (n = 6); and 15 best practices were identified to guide treatment post-NT, focusing on surgery (n = 7), pathology (n = 4), and follow-up (n = 3). Conclusions Using a modified Delphi consensus technique, best practice guidelines were developed focusing on the optimal standards for delivering NT to patients with localized PDAC. Given the prognostic importance of completing multimodality therapy, efforts to standardize and optimize the delivery of NT represent an immediate opportunity to decrease care variation and improve outcomes for patients with PDAC. Future research should focus on validating and implementing best practice standards into clinical practice.
Weight Loss in Parkinson’s Disease: No Evidence for Role of Small Intestinal Bacterial Overgrowth
DiBaise, John K. , Driver‐Dunckley, Erika , Mehta, Shyamal H. , Hoffman‐Snyder, Charlene , Lin, Tanya, Driver-Dunckley, Erika, Hoffman-Snyder, Charlene, Crowell, Michael D. , Adler, Charles H.

Mayo Clinic

Journal of Parkinson’s Disease | November 26, 2024 | Volume: 8 | Issue: 4 | Pages: 571-581

10.3233/jpd-181386 | PMID 30149465 Get It

Background and Objective: Weight loss and small intestinal bacterial overgrowth (SIBO) are common in Parkinson’s disease (PD). We aimed to study the relationship between weight loss and SIBO in PD. Methods: This was a cross-sectional study with a prospective, interventional component. Consecutive patients seen in the PD clinic who agreed to participate underwent extensive history, movement exam, SIBO breath testing and answered questionnaires. A subset of those in the weight loss group were treated with rifaximin for 14 days and returned 3 months later for an assessment of their weight, GI symptoms, quality of life and SIBO status. All analyses were adjusted for age and disease duration. Results: Fifty-one patients participated in the study; 37 without weight loss and 14 with weight loss. Total energy intake including the distribution of macronutrient intake was similar between groups while physical activity was less in those with weight loss. PD severity scores did not differ between groups; however, PD-specific quality of life scores were significantly worse for the summary index and the subscales of emotional well-being, social support and communication. The prevalence of constipation, dyspepsia and abdominal pain/discomfort was higher in those with weight loss. The prevalence of SIBO was 14% in the weight loss group and was not different between groups. Eight PD patients with weight loss were treated with rifaximin; no significant change in GI symptoms, quality of life or weight was seen 3 months later. Conclusion: Although a number of differences were identified in quality of life and gastrointestinal symptoms between groups with and without weight loss, SIBO was not associated with weight loss in patients with PD. Given the exploratory nature and small number of patients with weight loss, however, further study is suggested.
B-052 Celiac Disease Risk Assessment of HLA-DQ Typing in IgA Deficient Patients
Vanderboom, Patrick M. , Liu, Duan , Snyder, Michael

Mayo Clinic

Clinical Chemistry | October 2, 2024 | Volume: 70 | Issue: Supplement_1 | Pages: No page available

10.1093/clinchem/hvae106.414 Get It

Abstract Background Celiac disease (CeD) is a chronic autoimmune disorder triggered by the ingestion of gluten in persons with the genetic risk factors human leukocyte antigens (HLA)-DQ2 and DQ8. Diagnostic evaluation of patients with suspected CeD often includes serology tests for tissue transglutaminase (tTG) antibodies. While the presence of HLA-DQ2 or DQ8 is required for the initiation and development of CeD, the genetic risk associated with the various alleles is not equivalent. Previous studies in patients with normal total IgA demonstrated the risk gradients of various HLA-DQ2 and DQ8 heterodimers in CeD. However, the impact of both gene variants in IgA deficient patients has not been investigated. In this study, HLA-DQ2 and HLA-DQ8 as risk factors for tTG-IgG positivity in IgA deficient patients were evaluated. Methods Retrospective data was collected from a cohort of individuals (n=3,515) with IgA concentrations below the age-dependent reference interval with suspicion for CeD who were tested for HLA-DQ genotyping and tTG-IgG (reference interval < 6 U/mL) at Mayo Clinic Laboratories. Total IgA was measured using quantitative nephelometry (Siemens BN™ II System); HLA typing was performed using the reverse SSO DNA typing assay (LABType SSO kits). tTG-IgG was determined by enzyme-linked immunosorbent assay (QUANTA Lite R h-tTG, Werfen Diagnostics) on the Dynex Agility System. The prevalence and frequency distribution of HLA-DQ2 and DQ8 haplotypes were determined and the odds ratio (OR) was calculated to evaluate the risk gradient for tTG-IgG positivity based on different HLA-DQ variants. Results Among IgA deficient patients, 58% (n=2,041) expressed HLA-DQ2 or DQ8 haplotypes. Relative to patients without permissive alleles, patients homozygous for HLA-DQ2.5 exhibited a significantly increased risk for tTG-IgG positivity (OR = 10.98, 95% CI: 6.56-18.18, p < 0.001) while those homozygous for HLA-DQ2.2 and DQ8 did not (DQ2.2/DQ2.2_OR = 0.72, 95% CI: 0.04-3.44, p = 0.75; DQ8/DQ8_OR = 0.96, 95% CI: 0.05-4.64, p = 0.97). Patients heterozygous for HLA-DQ2.5 (DQ2.5/x) displayed a lower odds ratio relative to homozygous patients (OR = 3.31, 95% CI: 2.29-4.82, p < 0.001); however, the risk for tTG-IgG positivity increased in the presence of HLA-DQ2.2 (DQ2.5/DQ2.2_OR = 7.59, 95% CI: 4.48-12.65, p < 0.001) or HLA-DQ8 (DQ2.5/DQ8_OR = 6.26, 95% CI: 3.55-10.73, p < 0.001) alleles. Conversely, in the absence of HLA-DQ2.5, HLA-DQ2.2 heterozygotes (DQ2.2/x_OR = 2.80, 95% CI: 1.77-4.39, p < 0.001) and HLA-DQ8 heterozygotes (DQ8/x_OR = 0.99, 95% CI: 0.52-1.77, p = 0.99) displayed lower correlations with tTG-IgG positivity, suggesting a potential risk elevation for tTG-IgG positivity is associated with the combination of DQ2.5 and DQ2.2 or DQ8. Conclusions Our study indicates the risk gradient of HLA-DQ genes in IgA deficient patients. Overall, compared to patients without HLA-DQ2 or DQ8 haplotypes, the homozygous HLA-DQ2.5 genotype had the highest correlation with tTG-IgG positivity, followed by HLA-DQ2.5/DQ2.2 and HLA-DQ2.5/DQ8 heterodimers. The results suggest that HLA-DQ2.2 or HLA-DQ8 alone does not confer risk, but when in the presence of HLA-DQ2.5 these alleles may increase the risk for tTG-IgG positivity. Results from this study shed light on the risk of CeD in patients with IgA deficiency.
Gene-Specific Effects on Brain Volume and Cognition of TMEM106B in Frontotemporal Lobar Degeneration
Vandebergh, Marijne , Ramos, Eliana Marisa , Corriveau‐Lecavalier, Nick , Ramanan, Vijay K. , Kornak, John , Mester, Carly , Kolander, Tyler, Brushaber, Danielle , Staffaroni, Adam M. , Geschwind, Daniel H., Wolf, Amy , Kantarci, Kejal, Petrucelli, Leonard , Broeck, Marleen Van den , Wynants, Sarah , Baker, Matthew , Borrego‐Écija, Sergi , Barmada, Sami J. , Darby, R. Ryan , Domoto‐Reilly, Kimiko , Fields, Julie A. , Ghoshal, Nupur , Graff‐Radford, Neill R. , Grant, Ian , Huey, Edward D. , Kwan, Justin , Litvan, Irene , Masdeu, Joseph C. , Mendez, Mario F. , Onyike, Chiadi U. , Pascual, Belén , Pressman, Peter , Ritter, Aaron, Roberson, Erik D. , Snyder, Allison , Sullivan, Anna Campbell, Wint, Dylan , Heuer, Hilary W. , Forsberg, Leah K. , Boxer, Adam L. , Rosen, Howard J. , Rademakers, Rosa , Kantarci, Kejal , Brushaber, Danielle E, Wolf, Amy A, Gendron, Tania F , Van den Broeck, Marleen, Borrego-Écija, Sergi , Appleby, Brian , Barmada, Sami , Bozoki, Andrea C , Darby, Richard Ryan , Dickerson, Bradford Clark , Domoto-Reilly, Kimiko , Fields, Julie A , Galasko, Douglas , Ghoshal, Nupur , Honig, Lawrence S. , Hsiung, Gink-Yuek , Huey, Edward D , Irwin, David J , Knopman, David S. , Kwan, Justin Y., Léger, Gabriel C, Litvan, Irene , Onyike, Chiadi , Pascual, Belen , Pressman, Peter S, Roberson, Erik , Tartaglia, Maria Carmela , Wint, Dylan , Heuer, Hilary W , Forsberg, Leah K , Boxer, Adam , Rosen, Howard J , Boeve, Brad , Rademakers, Rosa , Kantarci, Kejal , Ramanan, Vijay K , Corriveau-Lecavalier, Nick , Snyder, Allison , Vandebergh, Marijne , Mester, Carly , Geschwind, Daniel H. , Gendron, Tania F. , Appleby, Brian S. , Clark, David, Galasko, Douglas , Hsiung, Ging‐Yuek Robin , Irwin, David J. , Knopman, David S. , Léger, Gabriel C. , Masdeu, Joseph C , Boeve, Bradley F.

Mayo Clinic

Neurology | September 25, 2024 | Volume: 103 | Issue: 8 | Pages: No page available

10.1212/wnl.0000000000209832 | PMID 39321401 Get It

Iltamiocel Autologous Cell Therapy for the Treatment of Female Stress Urinary Incontinence: A Double‐Blind, Randomized, Stratified, Placebo‐Controlled Trial
Kaufman, Melissa R. , Goldman, Howard B. , Chermansky, Christopher , Dmochowski, Roger R. , Peters, Kenneth M. , Quiroz, Lieschen H. , Bennett, Jason , Thomas, Sherry , Marguet, Charles G., Benson, Kevin , Wolter, Christopher , Katz, Daniel , Tarnay, Christopher M. , Antosh, Danielle D. , Heit, Michael , Rehme, Christian, Karram, Mickey M., Canestrari, Emanuele , Jankowski, Ron J. , Chermansky, Christopher J , Dmochowski, Roger , Lee, Una J , Wolter, Christopher E, Canestrari, Emanuele , Jankowski, Ron J , Chancellor, Michael B , KENNELLY, MICHAEL J. , Sokol, Eric R. , Katz, Daniel M., Snyder, Scott

Mayo Clinic

Neurourology and Urodynamics | September 16, 2024 | Volume: 43 | Issue: 8 | Pages: 2290-2299

10.1002/nau.25588 | PMID 39282854 Get It

ABSTRACTAimsThis study aimed to determine the efficacy and safety of iltamiocel investigational autologous muscle cell therapy in females with stress urinary incontinence (SUI).MethodsAdult females were randomized 2:1 to iltamiocel (150 × 106 cells) or placebo and stratified by severity and prior SUI surgery. The primary objective was efficacy based on the frequency of stress incontinence episodes (SIE) recorded in a 3‐day diary at 12 months posttreatment. After 12 months, placebo participants could elect to receive open‐label iltamiocel. Efficacy and safety analyses were performed using all patients as treated populations.ResultsThe study enrolled 311 patients, 297 were randomized to either iltamiocel (n = 199) or placebo (n = 98). Of the 295 participants that completed 12 months blinded follow‐up, the proportion achieving the primary endpoint of ≥ 50% SIE reduction was not statistically different between treatment groups (52% vs. 53.6%; p = 0.798). A significantly greater proportion of iltamiocel participants in the prior SUI surgery stratum group achieved ≥ 75% SIE reduction compared with placebo, (40% vs. 16%; p = 0.037). Treatment response was maintained at 24 months in 78.4% and 64.9% of iltamiocel participants who achieved ≥ 50% and ≥ 75% SIE reduction, respectively, at Month 12. Adverse events related to the treatment were reported in 19 (9.5%) iltamiocel participants and 6 (6.1%) placebo participants.ConclusionThe study did not meet its primary endpoint however, iltamiocel cell therapy is safe and may be ideally suited to female patients who have undergone prior surgery for SUI. Additional study in this group of patients with high unmet medical needs is warranted.Trial RegistrationClinicalTrials.gov identifier: NCT01893138; EudraCT number: 2014‐002919‐41.
Better cardiovascular health is associated with slowed clinical progression in autosomal dominant frontotemporal lobar degeneration variant carriers
VandeBunte, Anna M. , Staffaroni, Adam M. , Yaffe, Kristine , Ramos, Eliana Marisa , Rascovsky, Katya, Wong, Bonnie , Domoto‐Reilly, Kimiko , Snyder, Allison , Pressman, Peter , Mendez, Mario F. , Fields, Julie A. , Darby, Ryan, Masdeu, Joseph C. , Pasqual, Maria Belen, Ghoshal, Nupur , Mackenzie, Ian R. , Heuer, Hilary W. , Kramer, Joel H. , Boxer, Adam L. , Forsberg, Leah K. , Rosen, Howard J., Casaletto, Kaitlin B. , Domoto-Reilly, Kimiko , Snyder, Allison , Lee, Hyun Woo , Paolillo, Emily W. , Hsiung, Ging‐Yuek Robin , Saloner, Rowan , Tartaglia, Maria Carmela , Knopman, David S. , Bozoki, Andrea C , Litvan, Irene , Galasko, Douglas , Masdeu, Joseph C , Honig, Lawrence S. , Appleby, Brian S. , Boeve, Bradley F.

Mayo Clinic

Alzheimer's & Dementia | September 6, 2024 | Volume: 20 | Issue: 10 | Pages: 6820-6833

10.1002/alz.14172 | PMID 39240048 Get It

AbstractINTRODUCTIONCardiovascular health is important for brain aging, yet its role in the clinical manifestation of autosomal dominant or atypical forms of dementia has not been fully elucidated. We examined relationships between Life's Simple 7 (LS7) and clinical trajectories in individuals with autosomal dominant frontotemporal lobar degeneration (FTLD).METHODSTwo hundred forty‐seven adults carrying FTLD pathogenic genetic variants (53% asymptomatic) and 189 non‐carrier controls completed baseline LS7, and longitudinal neuroimaging and neuropsychological testing.RESULTSAmong variant carriers, higher baseline LS7 is associated with slower accumulation of frontal white matter hyperintensities (WMHs), as well as slower memory and language declines. Higher baseline LS7 associated with larger baseline frontotemporal volume, but not frontotemporal volume trajectories.DISCUSSIONBetter baseline cardiovascular health related to slower cognitive decline and accumulation of frontal WMHs in autosomal dominant FTLD. Optimizing cardiovascular health may be an important modifiable approach to bolster cognitive health and brain integrity in FTLD.Highlights Better cardiovascular health associates with slower cognitive decline in frontotemporal lobar degeneration (FTLD). Lifestyle relates to the accumulation of frontal white matter hyperintensities in FTLD. More optimal cardiovascular health associates with greater baseline frontotemporal lobe volume. Optimized cardiovascular health relates to more favorable outcomes in genetic dementia.